FIELD: biotechnology.
SUBSTANCE: disclosed is a method of treating cell proliferation disorders in a mammal, comprising administering a peptide compound containing (d-Bpa)(d-Ser)(d-Trp)(d-Ser)(d-Phe-2,3,4,5,6-F)(d-Cha), or a pharmaceutically acceptable salt thereof, wherein the peptide compound additionally contains an attached or conjugated cell-permeable molecule, wherein the leukocyte content in the mammal is less than approximately 10000 leukocytes per microliter (WBC/mcl) of blood.
EFFECT: present invention can be used in treating tumors.
46 cl, 13 tbl, 6 ex, 20 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDES AND PEPTIDOMIMETICS IN COMBINATION WITH CONTROL POINT INHIBITING AGENTS FOR TREATING CANCER | 2016 |
|
RU2739201C2 |
| SELF-ASSEMBLED PEPTIDES IN PREVENTION AND TREATMENT OF CAVITIES ACCOMPANIED BY FORMATION OF CAVITIES | 2020 |
|
RU2828353C2 |
| PEPTIDE ANALOG OF ACYLATED OXYNTOMODULIN | 2018 |
|
RU2752787C1 |
| USE OF THE ANTI-O-ACETYLATED GANGLIOSIDE GD2 ANTIBODY FOR IMPROVING THE THERAPEUTIC POTENTIAL OF DRUGS | 2017 |
|
RU2771173C2 |
| STRUCTURES HAVING SIRP-ALPHA DOMAIN OR ITS VERSION | 2016 |
|
RU2740672C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
| IMPROVED PEPTIDE DRUGS FOR TREATMENT OF NASH AND OTHER DISORDERS | 2019 |
|
RU2790209C2 |
| THERAPEUTIC USE OF LONG-ACTING TRIPLE AGONIST CONJUGATE HAVING ACTIVITIES ON ALL GLUCAGON/GLP-1/GIP RECEPTORS FOR TREATING LUNG DISEASE | 2020 |
|
RU2829342C1 |
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
| PEPTIDES AND THEIR USE IN TREATMENT OF DISEASES, DISORDERS OR CONDITIONS ASSOCIATED WITH MUTANT p53 | 2017 |
|
RU2762089C2 |
